Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients

SUMMIT, N.J., June 24, 2026 /PRNewswire/ — Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor®;…

Read the full release →

News provided by PR Newswire.